NanoViricides' Anti-Virus Technology Published in Bionanotechnology II: Global Prospects

(Nanowerk News) NanoViricides, Inc. announced today that information about its novel, proprietary anti-virus platform technology has been published in the book Bionanotechnology II: Global Prospects. The chapter entitled "Nanoviricides - A Novel Approach to Antiviral Therapeutics" provides an in-depth presentation of the NanoViricides platform technology, evidence for how nanoviricides are believed to act plus dramatic results of nanoviricides specifically targeting certain viral diseases, such as HIV and the ocular disease, epidemic keratoconjunctivitis (EKC).
The chapter introduces the novel NanoViricides nanotechnology that possesses potent antiviral efficacy by targeting the mechanisms by which viruses attach or bind to cells. A nanoviricide® is believed to act like a decoy of a human cell. When the virus sees the appropriate cell binding mimic displayed on a nanoviricide, the virus binds to it. The Company believes that the flexible nanoviricide enables cooperative binding of the nanoviricide to additional sites on the virus surface in a velcro-like effect. This maximization of virus binding would lead to the nanoviricide spreading onto the virus particle, fusing with the virus surface, and then engulfing the virus. In the process, the coat proteins that the virus uses for binding to cells would be expected to become unavailable. This highly targeted attack would lead to the loss of the viral coat proteins and the nanoviricide may further dismantle the engulfed virus capsid. The loss of virus particle integrity would neutralize the virus, making the virus non-infectious.
The publisher of the book, CRC Press, states "The impact and importance of nanotechnology continues to grow, and nanomedicine and biotechnology have become areas of increased development. Bionanotechnology II: Global Prospects, David Reisner Editor, a follow-up to the editor's highly successful first volume, contains 26 entirely new contributions that provide a broad survey of research shaping this critical field. With coverage of technical and non-technical areas, the book reports on a wide variety of activity from around the world. It discusses the role of nanotechnology in novel medical devices, bioanalytical technologies, and nanobiomaterials".
About NanoViricides
NanoViricides, Inc. ( ) is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.
Source: NanoViricides (press release)
Subscribe to a free copy of one of our daily
Nanowerk Newsletter Email Digests
with a compilation of all of the day's news.
These articles might interest you as well: